Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Baron (Groningen, Netherlands), B. Flokstra-De Blok (Groningen, Netherlands), H. Kerstjens (Groningen, Netherlands), G. Koopmans-Klein ( Leusden, Netherlands), D. Price (Singapore, Singapore), A. Sellink (Den Haag, Netherlands), I. Tsiligianni (Crete, Greece), J. Kocks (Groningen, Netherlands). High use of SABAs is associated with higher exacerbation frequency. 2273

Member's Comments

No comment yet.

Related content which might interest you: Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Correlates of high levels of use of short-acting beta agonists in asthma Source: Annual Congress 2011 - Respiratory epidemiology: quality of life, therapy and socioeconomics Year: 2011 Increasing risk of exacerbation and mortality associated with increasing frequency and severity of exacerbations in COPD patients: EXACOS-UK Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021 Higher resource use and lower asthma-related QOL in patients with severe or difficult-to-treat asthma Source: Eur Respir J 2003; 22: Suppl. 45, 296s Year: 2003 Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler usage and normal daily activities Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Low level of FoxP3 in bronchial asthma (BA) is associated with frequent exacerbations Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012 Different causes of COPD exacerbation: unable or not to use bronchodilator drugs and journey to high altitude Source: Eur Respir J 2006; 28: Suppl. 50, 31s Year: 2006 Asthma symptoms, SABA use, and lung function before and after a moderate or severe exacerbation Source: International Congress 2017 – Many faces of asthma and allergies Year: 2017 Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Factors associated with high levels of exhaled NO in children using asthma medication Source: Annual Congress 2011 - Inflammation and genes in childhood asthma Year: 2011 Patterns of symptom change measured using the EXACT diary associated with prescription of corticosteroids or antibiotics in COPD exacerbations Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA) Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Are patients who overuse short acting β2-agonists more likely to report high levels of asthma symptoms? Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003 Fast time estimation is associated with high levels of depression in COPD patients Source: Virtual Congress 2020 – Diagnosis and management of COPD Year: 2020 Increased respiratory symptoms in COPD patients on withdrawal of therapy: evidence of long-term efficacy gains with formoterol turbuhaler Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002 Low hematocrit as predictor of exacerbation frequency in COPD patients Source: Annual Congress 2010 - Exacerbations and COPD and rehabilitation Year: 2010 Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006